Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.
1. A method of treating a neurodegenerative disease in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound having a structure represented by a formula selected from:
wherein R 2 is hydrogen;
wherein L 1 is unsubstituted methylene;
wherein R 1 is R 20 -substituted or unsubstituted tetrahydrofuranyl or R 20 -substituted or unsubstituted tetrahydropyranyl; and
wherein each occurrence of R 20 is independently halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, substituted or unsubstituted monophosphate, substituted or unsubstituted diphosphate, substituted or unsubstituted triphosphate, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl,
or a pharmaceutically acceptable salt thereof, wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic lateral sclerosis.
2. The method of claim 1 , wherein the compound is administered as a pharmaceutical composition comprising said compound and a pharmaceutically acceptable excipient.
3. The method of claim 1 , wherein R 1 is R 20 -substituted tetrahydrofuranyl or R 20 -substituted tetrahydropyranyl.
4. The method of claim 1 , wherein the compound has a structure represented by a formula:
wherein z1 is 0, 1, 2, or 3.
5. The method of claim 1 , wherein the compound has a structure represented by a formula selected from:
wherein z2 is 0, 1, 2, 3, 4, or 5.
6. The method of claim 1 , wherein the neurodegenerative disease is Alzheimer's disease.
7. The method of claim 1 , wherein the neurodegenerative disease is Parkinson's disease.
8. The method of claim 1 , wherein the neurodegenerative disease is Huntington's disease.
9. The method of claim 1 , wherein the neurodegenerative disease is Amyotrophic lateral sclerosis.
10. The method of claim 1 , wherein the effective amount is a therapeutically effective amount.
11. The method of claim 1 , wherein the effective amount is a prophylactically effective amount.